GXI Stock Overview
Manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 0/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
New Production Lines In Lohr And Skopje Will Improve Efficiency
Gerresheimer AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €51.85 |
| 52 Week High | €109.70 |
| 52 Week Low | €49.56 |
| Beta | 0.95 |
| 1 Month Change | -31.87% |
| 3 Month Change | -20.72% |
| 1 Year Change | -47.57% |
| 3 Year Change | -27.58% |
| 5 Year Change | -23.69% |
| Change since IPO | 35.20% |
Recent News & Updates
Earnings Troubles May Signal Larger Issues for Gerresheimer (ETR:GXI) Shareholders
Apr 19
It's Down 32% But Gerresheimer AG (ETR:GXI) Could Be Riskier Than It Looks
Apr 11Gerresheimer (ETR:GXI) Will Pay A Dividend Of €1.25
Apr 10Recent updates
Earnings Troubles May Signal Larger Issues for Gerresheimer (ETR:GXI) Shareholders
Apr 19It's Down 32% But Gerresheimer AG (ETR:GXI) Could Be Riskier Than It Looks
Apr 11Gerresheimer (ETR:GXI) Will Pay A Dividend Of €1.25
Apr 10Gerresheimer (ETR:GXI) Has Announced A Dividend Of €1.25
Mar 05Why Investors Shouldn't Be Surprised By Gerresheimer AG's (ETR:GXI) 25% Share Price Surge
Feb 25
Expansion Into High-Margin Biologics And Devices Indicates Strong Future Prospects
Feb 09 Strategic expansion into high-margin segments like drug delivery systems and ready-to-use vials could enhance revenue and EBITDA margins significantly.Is Gerresheimer (ETR:GXI) Using Too Much Debt?
Jan 12Is It Time To Consider Buying Gerresheimer AG (ETR:GXI)?
Dec 26Gerresheimer AG Just Missed EPS By 14%: Here's What Analysts Think Will Happen Next
Oct 03Is Gerresheimer (ETR:GXI) Using Too Much Debt?
Sep 29Gerresheimer AG's (ETR:GXI) Share Price Matching Investor Opinion
Aug 31Shareholders Will Most Likely Find Gerresheimer AG's (ETR:GXI) CEO Compensation Acceptable
May 30Gerresheimer AG's (ETR:GXI) Share Price Matching Investor Opinion
May 22An Intrinsic Calculation For Gerresheimer AG (ETR:GXI) Suggests It's 40% Undervalued
May 03Analysts Are Updating Their Gerresheimer AG (ETR:GXI) Estimates After Its First-Quarter Results
Apr 14Gerresheimer's (ETR:GXI) Dividend Will Be €1.25
Apr 12Gerresheimer (ETR:GXI) Has A Somewhat Strained Balance Sheet
Apr 10Gerresheimer (ETR:GXI) Has Announced A Dividend Of €1.25
Feb 25Investors Still Waiting For A Pull Back In Gerresheimer AG (ETR:GXI)
Feb 10At €92.85, Is Gerresheimer AG (ETR:GXI) Worth Looking At Closely?
Jan 23Are Investors Undervaluing Gerresheimer AG (ETR:GXI) By 28%?
Jan 03Is Gerresheimer (ETR:GXI) Using Too Much Debt?
Dec 15When Should You Buy Gerresheimer AG (ETR:GXI)?
Oct 19An Intrinsic Calculation For Gerresheimer AG (ETR:GXI) Suggests It's 42% Undervalued
Oct 01Is Gerresheimer (ETR:GXI) Using Too Much Debt?
Aug 26Should You Investigate Gerresheimer AG (ETR:GXI) At €105?
Jul 06Gerresheimer AG's (ETR:GXI) Intrinsic Value Is Potentially 94% Above Its Share Price
Jun 18Gerresheimer (ETR:GXI) Is Paying Out A Dividend Of €1.25
Apr 05Is Gerresheimer (ETR:GXI) A Risky Investment?
Mar 17Gerresheimer's (ETR:GXI) Dividend Will Be €1.25
Feb 27What Does Gerresheimer AG's (ETR:GXI) Share Price Indicate?
Feb 15Is Gerresheimer (ETR:GXI) Using Too Much Debt?
Nov 18Is Now An Opportune Moment To Examine Gerresheimer AG (ETR:GXI)?
Sep 06Is Gerresheimer (ETR:GXI) A Risky Investment?
Aug 18Gerresheimer (ETR:GXI) Is Due To Pay A Dividend Of €1.25
May 31Gerresheimer (ETR:GXI) Will Pay A Dividend Of €1.25
May 16Gerresheimer (ETR:GXI) Has Announced A Dividend Of €1.25
May 02Gerresheimer (ETR:GXI) Has Affirmed Its Dividend Of €1.25
Apr 18Shareholder Returns
| GXI | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -2.3% | 6.4% | 4.1% |
| 1Y | -47.6% | -12.4% | 8.4% |
Return vs Industry: GXI underperformed the German Life Sciences industry which returned -12.4% over the past year.
Return vs Market: GXI underperformed the German Market which returned 8.4% over the past year.
Price Volatility
| GXI volatility | |
|---|---|
| GXI Average Weekly Movement | 7.2% |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: GXI has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: GXI's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1864 | 13,632 | Dietmar Siemssen | www.gerresheimer.com |
Gerresheimer AG, together with its subsidiaries, manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally. It operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The company offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and glass bottles and jars, as well as caps, closures, applicators, and accessories; development, industrialization and contract manufacturing of drug delivery programs; project and quality management; and drug delivery systems, including inhalers, injection/auto injectors, pen injectors, infusion systems, and inhalation assessment, autoinjector, and other services.
Gerresheimer AG Fundamentals Summary
| GXI fundamental statistics | |
|---|---|
| Market cap | €1.79b |
| Earnings (TTM) | €78.70m |
| Revenue (TTM) | €2.09b |
22.8x
P/E Ratio0.9x
P/S RatioIs GXI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GXI income statement (TTM) | |
|---|---|
| Revenue | €2.09b |
| Cost of Revenue | €1.48b |
| Gross Profit | €604.92m |
| Other Expenses | €526.22m |
| Earnings | €78.70m |
Last Reported Earnings
Feb 28, 2025
Next Earnings Date
Jul 10, 2025
| Earnings per share (EPS) | 2.28 |
| Gross Margin | 28.95% |
| Net Profit Margin | 3.77% |
| Debt/Equity Ratio | 148.3% |
How did GXI perform over the long term?
See historical performance and comparisonDividends
2.4%
Current Dividend Yield55%
Payout RatioDoes GXI pay a reliable dividends?
See GXI dividend history and benchmarks| Gerresheimer dividend dates | |
|---|---|
| Ex Dividend Date | Jun 06 2025 |
| Dividend Pay Date | Jun 10 2025 |
| Days until Ex dividend | 46 days |
| Days until Dividend pay date | 50 days |
Does GXI pay a reliable dividends?
See GXI dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/20 15:28 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2025/02/28 |
| Annual Earnings | 2024/11/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gerresheimer AG is covered by 36 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gaurav Jain | Barclays |
| Scott Bardo | Berenberg |
| Victoria Lambert | Berenberg |